Agilent Technologies Competitors

Agilent Technologies (NYSE:A) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Agilent Technologies and Thermo Fisher Scientific's gross revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Agilent Technologies. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Dividends

Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 1 consecutive years and Thermo Fisher Scientific has increased its dividend for 3 consecutive years.

Profitability

This table compares Agilent Technologies and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Agilent Technologies and Thermo Fisher Scientific, as provided by MarketBeat.

Agilent Technologies presently has a consensus price target of $106.1850, suggesting a potential downside of 21.10%. Thermo Fisher Scientific has a consensus price target of $527.05, suggesting a potential upside of 6.92%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Agilent Technologies.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Thermo Fisher Scientific beats Agilent Technologies on 11 of the 17 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Volatility & Risk

Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Agilent Technologies and Illumina, as reported by MarketBeat.com.

Agilent Technologies currently has a consensus target price of $106.1850, suggesting a potential downside of 21.10%. Illumina has a consensus target price of $370.5789, suggesting a potential downside of 7.12%. Given Illumina's higher possible upside, analysts clearly believe Illumina is more favorable than Agilent Technologies.

Earnings and Valuation

This table compares Agilent Technologies and Illumina's revenue, earnings per share (EPS) and valuation.

Illumina has lower revenue, but higher earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Agilent Technologies and Illumina's net margins, return on equity and return on assets.

Summary

Illumina beats Agilent Technologies on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Mettler-Toledo International (NYSE:MTD) are both large-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Profitability

This table compares Agilent Technologies and Mettler-Toledo International's net margins, return on equity and return on assets.

Volatility & Risk

Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Agilent Technologies and Mettler-Toledo International's top-line revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than Mettler-Toledo International. Agilent Technologies is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Agilent Technologies and Mettler-Toledo International, as provided by MarketBeat.

Agilent Technologies currently has a consensus price target of $106.1850, suggesting a potential downside of 21.10%. Mettler-Toledo International has a consensus price target of $971.3750, suggesting a potential downside of 24.25%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats Agilent Technologies on 7 of the 13 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Institutional & Insider Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Agilent Technologies and Bio-Rad Laboratories' revenue, earnings per share and valuation.

Bio-Rad Laboratories has lower revenue, but higher earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Agilent Technologies and Bio-Rad Laboratories, as provided by MarketBeat.

Agilent Technologies currently has a consensus price target of $106.1850, indicating a potential downside of 21.10%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 11.80%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Agilent Technologies.

Profitability

This table compares Agilent Technologies and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Volatility & Risk

Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Agilent Technologies on 8 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Valuation and Earnings

This table compares Agilent Technologies and Waters' top-line revenue, earnings per share and valuation.

Agilent Technologies has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

91.8% of Waters shares are held by institutional investors. 1.5% of Waters shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Agilent Technologies and Waters' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Agilent Technologies and Waters, as reported by MarketBeat.

Agilent Technologies currently has a consensus target price of $106.1850, indicating a potential downside of 21.10%. Waters has a consensus target price of $224.20, indicating a potential downside of 25.24%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Waters.

Summary

Agilent Technologies beats Waters on 8 of the 14 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Risk and Volatility

Bio-Techne has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Bio-Techne and Agilent Technologies' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Bio-Techne and Agilent Technologies' top-line revenue, earnings per share and valuation.

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bio-Techne and Agilent Technologies, as provided by MarketBeat.com.

Bio-Techne currently has a consensus price target of $367.50, suggesting a potential downside of 12.20%. Agilent Technologies has a consensus price target of $106.1850, suggesting a potential downside of 21.10%. Given Bio-Techne's higher possible upside, equities analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dividends

Bio-Techne pays an annual dividend of $1.28 per share and has a dividend yield of 0.3%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Bio-Techne pays out 33.2% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bio-Techne has raised its dividend for 1 consecutive years and Agilent Technologies has raised its dividend for 1 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.